A. Rousseau

V. de Lédinghen, D. Sautereau, P. Marquet, 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Ribavirin in chronic hepatitis C: past and future

P. Marquet, S. Alain, F. Denis, 2009, Expert review of anti-infective therapy.

Ribavirin: Past, present and future.

D. Sautereau, P. Marquet, S. Alain, 2016, World journal of hepatology.

Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin

P. Marquet, A. Tran, C. Trépo, 2016, Therapeutic drug monitoring.

Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions

M. Estenne, P. Marquet, C. Knoop, 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Population pharmacokinetics and Bayesian estimation of mycophenolate mofetil in patients with autoimmune hepatitis

A. Prémaud, P. Marquet, J. Woillard, 2021, British journal of clinical pharmacology.

An animal model for the study of chronopharmacokinetics of drugs and application to methotrexate and vinorelbine.

A. Prémaud, P. Marquet, M. Laurentie, 2002, Toxicology and applied pharmacology.

Donor P‐gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long‐Term Follow‐Up

P. Marquet, N. Picard, M. Essig, 2010, Clinical pharmacology and therapeutics.

Donor Pgp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients with long term follow-up

P. Marquet, N. Picard, Y. Meur, 2010 .

Donor P‐gp Polymorphisms Strongly Influence Renal Function and Graft Loss in a Cohort of Renal Transplant Recipients on Cyclosporine Therapy in a Long‐Term Follow‐Up

P. Marquet, N. Picard, Y. Meur, 2010, Clinical pharmacology and therapeutics.

Non-invasive detection of hepatic amyloidosis: FibroScan, a new tool

D. Sautereau, A. Fauchais, A. Jaccard, 2011, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Post-transplant lymphoproliferative disease (PTLD): Pharmacological, virological and other determinants.

P. Marquet, Jana Stojanova, A. Rousseau, 2011, Pharmacological research.

Relationship between psychotropic drugs and thyroid function: a review.

P. Marquet, G. Lachâtre, A. Rousseau, 1998, Toxicology and applied pharmacology.

Synthesis and antithyroid activity of pyridine, pyrimidine and pyrazine derivatives of thiazole-2-thiol and 2-thiazoline-2-thiol.

A. Rousseau, F. Comby, J. Lagorce, 1993, Chemical & pharmaceutical bulletin.

Risk of diarrhea in a long-term cohort of renal transplant patients given mycophenolate mofetil : the significant role of the UGT 1 A 8 * 2 variant allele

P. Marquet, N. Picard, Y. Meur, 2017 .

Adherence profiles in kidney transplant patients: Causes and consequences.

P. Marquet, N. Kamar, M. Essig, 2019, Patient education and counseling.

Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation

P. Marquet, L. Rostaing, E. Thervet, 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions

M. De Backer, J. Kovarik, M. Estenne, 2003, Transplantation.

Patient Characteristics Influencing Ciclosporin Pharmacokinetics and Accurate Bayesian Estimation of Ciclosporin Exposure in Heart, Lung and Kidney Transplant Patients

Pierre Marquet, P. Marquet, Y. Meur, 2006, Clinical pharmacokinetics.

Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrospray mass spectrometry.

P. Marquet, J. Gaulier, G. Lachâtre, 1999, Journal of chromatography. B, Biomedical sciences and applications.

eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?

D. Sautereau, M. Essig, A. Rousseau, 2015, Liver international : official journal of the International Association for the Study of the Liver.

Comparison of Liquid Chromatography-Tandem Mass Spectrometry with a Commercial Enzyme-Multiplied Immunoassay for the Determination of Plasma MPA in Renal Transplant Recipients and Consequences for Therapeutic Drug Monitoring

A. Prémaud, P. Marquet, Y. Le Meur, 2004, Therapeutic drug monitoring.

Determination of Mycophenolic Acid Plasma Levels in Renal Transplant Recipients Co-administered Sirolimus: Comparison of an Enzyme Multiplied Immunoassay Technique (EMIT) and Liquid Chromatography–Tandem Mass Spectrometry

A. Prémaud, P. Marquet, N. Picard, 2006, Therapeutic drug monitoring.

Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods

A. Prémaud, P. Marquet, O. Toupance, 2005, Therapeutic drug monitoring.

A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil

A. Prémaud, P. Marquet, O. Toupance, 2005, Clinical pharmacokinetics.

The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.

C. Férec, P. Jousset, C. Charasse, 2016, Journal of the American Society of Nephrology : JASN.

Bayesian Forecasting of Oral Cyclosporin Pharmacokinetics in Stable Lung Transplant Recipients With and Without Cystic Fibrosis

M. Estenne, P. Marquet, J. Debord, 2003, Therapeutic drug monitoring.

Population pharmacokinetics of cyclosporine in cardiopulmonary transplant recipients.

P. Marquet, F. Saint‐Marcoux, A. Rousseau, 2006, Therapeutic drug monitoring.

Large Scale Analysis of Routine Dose Adjustments of Mycophenolate Mofetil Based on Global Exposure in Renal Transplant Patients

A. Prémaud, P. Marquet, J. Debord, 2011, Therapeutic drug monitoring.

Bayesian Estimation of Methotrexate Pharmacokinetic Parameters and Area Under the Curve in Children and Young Adults with Localised Osteosarcoma

P. Marquet, C. Sabot, J. Debord, 2002, Clinical pharmacokinetics.

Population Pharmacokinetic Modelling and Design of a Bayesian Estimator for Therapeutic Drug Monitoring of Tacrolimus in Lung Transplantation

M. Estenne, P. Marquet, C. Pison, 2012, Clinical Pharmacokinetics.

Population Pharmacokinetics and Bayesian Estimation of Tacrolimus Exposure in Renal Transplant Recipients on a New Once-Daily Formulation

A. Prémaud, S. Urien, P. Marquet, 2010, Clinical pharmacokinetics.

Sensitive microanalysis of imipramine and desipramine in single rat thyroids by gas chromatography-mass spectrometry.

P. Marquet, G. Lachâtre, A. Rousseau, 1997, Journal of chromatography. B, Biomedical sciences and applications.

Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation

P. Marquet, N. Undre, J. Debord, 2010, Therapeutic drug monitoring.

Evaluation of Longitudinal Exposure to Tacrolimus as a Risk Factor of Chronic Kidney Disease Occurrence Within the First-year Post-Liver Transplantation

X. Causse, A. Prémaud, P. Marquet, 2020, Transplantation.

Influence of sampling-time error on cyclosporine measurements nominally at 2 hours after administration.

M. Estenne, P. Marquet, C. Knoop, 2003, Clinical chemistry.

Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients

P. Marquet, O. Toupance, Y. Meur, 2006, Clinical pharmacokinetics.

Determination of Trimeprazine and Its Main Metabolites in Mouse Serum and Thyroid by Liquid Chromatography-Electrospray-Mass Spectrometry

P. Marquet, A. Rousseau, J. Buxeraud, 1998 .

Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation

P. Marquet, N. Kamar, M. Essig, 2016, Transplantation.

Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs

Pierre Marquet, P. Marquet, Annick Rousseau, 2002, Fundamental & clinical pharmacology.

Limited Sampling Models and Bayesian Estimation for Mycophenolic Acid Area under the Curve Prediction in Stable Renal Transplant Patients Co-Medicated with Ciclosporin or Sirolimus

P. Marquet, P. Wallemacq, J. Bosmans, 2009, Clinical pharmacokinetics.

Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies

Pierre Marquet, Franck Saint-Marcoux, M. Estenne, 2005, Clinical pharmacokinetics.

Association of sirolimus adverse effects with m-TOR, p70S6K or Raptor polymorphisms in kidney transplant recipients

P. Marquet, L. Rostaing, N. Kamar, 2012, Pharmacogenetics and genomics.

Exposure to Mycophenolic Acid Better Predicts Immunosuppressive Efficacy Than Exposure to Calcineurin Inhibitors in Renal Transplant Patients

A. Prémaud, P. Marquet, Y. Meur, 2014, Clinical pharmacology and therapeutics.

Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial

P. Marquet, G. Hoizey, Y. Le Meur, 2010, Transplantation.

An adjustable predictive score of graft survival in kidney transplant patients and the levels of risk linked to de novo donor-specific anti-HLA antibodies

Pierre Marquet, Matthias Büchler, Eliza Munteanu, 2017, PloS one.

Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C

P. Marquet, P. Calès, F. Lunel, 2008, Hepatology.

Ciclosporin Population Pharmacokinetics and Bayesian Estimation in Thoracic Transplant Recipients

A. Prémaud, P. Marquet, N. Kamar, 2013, Clinical Pharmacokinetics.

Inhibition of T-cell activation and proliferation by mycophenolic acid in patients awaiting liver transplantation: PK/PD relationships.

A. Prémaud, P. Marquet, L. Rostaing, 2011, Pharmacological research.

Stability of Ribavirin Concentrations Depending on the Type of Blood Collection Tube and Preanalytical Conditions

P. Marquet, F. Sauvage, G. Lachâtre, 2010, Therapeutic drug monitoring.

Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC0–12 monitoring in cardiac transplant recipients over the first year post-transplantation

P. Marquet, T. Dantoine, J. Debord, 2003, European Journal of Clinical Pharmacology.

Polymorphisms in type I and II inosine monophosphate dehydrogenase genes and association with clinical outcome in patients on mycophenolate mofetil

P. Marquet, R. V. van Schaik, N. Picard, 2010, Pharmacogenetics and genomics.

Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation

P. Marquet, N. Kamar, M. Essig, 2016, Transplantation.